|1.||Beloborodova, E I: 2 articles (01/2005 - 01/2002)|
|2.||Shalovaĭ, A A: 2 articles (01/2005 - 01/2002)|
|3.||Vnushinskaia, M A: 2 articles (01/2005 - 01/2002)|
|4.||Rachkovskiĭ, M I: 2 articles (01/2005 - 01/2002)|
|5.||Sokolova, T M: 1 article (03/2012)|
|6.||Shuvalov, A N: 1 article (03/2012)|
|7.||Demina, O K: 1 article (01/2009)|
|8.||Agafonov, A P: 1 article (01/2009)|
|9.||Drozdov, I G: 1 article (01/2009)|
|10.||Sementsova, A O: 1 article (01/2009)|
01/01/2009 - "Therefore, Reaferon-ES lipint could be recommended for prophylaxis of the infection due not only to the season strains of the influenza virus, but also to the strains of the avian influenza virus."
01/01/2002 - "[Clinical response to combined treatment with reaferon and iodantipirin in patients with chronic HCV- and HBV-infection]."
09/01/1997 - "In Ebola infection a combination of ridostin and reaferon appreciably prolonged the mean life span: by 2.9 days (p = 0.04). "
01/01/1996 - "In progredient infection an early administration of reaferon in combination with thymogen is thought valid which in many patients is sufficient to prevent the disease transformation into a chronic form."
05/01/1995 - "In the Ebola infection combined administration of ridostin and reaferon caused an essential increase in the mean lifespan of the animals by 2.9 days (p = 0.04). "
01/01/2002 - "In a month, the patients started on reaferon given for therapy of hepatitis. "
01/01/1994 - "[The use of reaferon in treating patients with protracted viral hepatitis]."
01/01/1994 - "The paper reports the results of a randomized clinicoimmunological trial of domestic recombinant alpha 2-interferon (reaferon) in 30 patients with protracted viral hepatitis (27 subjects had viral hepatitis B and 3 patients HBV + HDV-coinfection). "
01/01/2005 - "[Combined treatment with reaferon and iodantipirin in patients with chronic viral hepatitides B and C]."
03/01/1990 - "[Reaferon treatment in acute HBsAG-positive viral hepatitis]."
|3.||Chronic Hepatitis B
01/01/2005 - "To examine clinical efficacy of combined therapy with reaferon and iodantipirin in patients with chronic hepatitis B and C of moderate activity. "
06/01/1989 - "Treatment of patients suffering from chronic hepatitis B with recombinant leukocytic interferon (reaferon) increased the levels of circulating interferon and activated interferon-dependent enzymes such as 2-5A-synthetase and histone kinase. "
|4.||Respiratory Tract Infections (Respiratory Tract Infection)
05/01/1988 - "[Prophylactic efficacy of reaferon in viral hepatitis A and acute respiratory infections in children]."
05/01/1988 - "On the whole, during that period hepatitis A morbidity in both test and control groups of children was the same (5.1% and 4.9% respectively), but among children of nursery age receiving Reaferon the incidence of hepatitis A and acute respiratory viral infections was lower than among those receiving the placebo, though this difference was statistically significant only for cases of acute respiratory infections."
10/01/1991 - "For the prophylaxis of respiratory infections the use of Reaferon is advisable 3-4 weeks prior to the beginning of the epidemic and then, when the first cases of infection are registered, the course of prophylaxis with Dibasol should be carried out."
05/01/1989 - "In combined use of a lysate of destroyed tumor cells (DTC) and reaferon the best results were obtained with regard to an increase in the latent period of tumor development, differences in the tumor size, and increase in the survival time of the experimental animals as compared with the control group. "
05/01/1989 - "In 75% of the animals given DTC and reaferon no tumors were observed up to 113 days. "
05/01/1989 - "The antitumor and immunomodulating effect of reaferon was demonstrated in Syrian hamsters bearing tumors induced by cells transformed by HSV-1 DNA (the EH/A-44 strain). "
07/01/1994 - "The maximal anti-tumor and immunomodulating effect was obtained by combined use of preimmunization with tumor cells and simultaneous administration of reaferon or interferon inducers, larifan and rhidostin. "
07/01/1994 - "Interferon inducers larifan and rhidostin, and reaferon were shown to exert an inhibiting antitumor effect manifested in the prolongation of the incubation period, decrease of the size of tumors, and longer survival of the animals. "
|2.||Interferon-alpha (Interferon Alfa)
|6.||Arachidonic Acid (Vitamin F)
|1.||Combination Drug Therapy (Combination Chemotherapy)